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hibit the phagocytic response to infection, allow bacterial
replication, and promote epithelial injury.
Three effector proteins of the ExoS regulon have been
identified (2). ExoS is an ADP-ribosyltransferase. Host target
proteins modified by ExoS include members of the H- and
K-Ras family of proteins, vimentin, the Fc region of IgG3, and
apolipoprotein A1 (4, 5). Of these targets, ADP-ribosylation of
Ras has been correlated to the uncoupling of Ras-mediated
signal transduction in PC-12 neuronal cells (6). Two additional
effector proteins, ExoT and ExoU, have been identified. ExoU
expression is correlated with acute cytotoxicity and lung
damage, but the role of ExoT remains elusive (7). Here, we
report the identification of an extracellular adenylate cyclase,
ExoY, a fourth effector protein of the ExoS regulon.

ABSTRACT
The exoenzyme S regulon is a set of coordinately regulated virulence genes of Pseudomonas aeruginosa.
Proteins encoded by the regulon include a type III secretion
and translocation apparatus, regulators of gene expression,
and effector proteins. The effector proteins include two enzymes with ADP-ribosyltransferase activity (ExoS and ExoT)
and an acute cytotoxin (ExoU). In this study, we identified
ExoY as a fourth effector protein of the regulon. ExoY is
homologous to the extracellular adenylate cyclases of Bordetella pertussis (CyaA) and Bacillus anthracis (EF). The homology among the three adenylate cyclases is limited to two short
regions, one of which possesses an ATP-binding motif. In
assays for adenylate cyclase activity, recombinant ExoY
(rExoY) catalyzed the formation of cAMP with a specific
activity similar to the basal activity of CyaA. In contrast to
CyaA and EF, rExoY activity was not stimulated or activated
by calmodulin. A 500-fold stimulation of activity was detected
following the addition of a cytosolic extract from Chinese
hamster ovary (CHO) cells. These results indicate that a
eukaryotic factor, distinct from calmodulin, enhances rExoY
catalysis. Site-directed mutagenesis of residues within the
putative active site of ExoY abolished adenylate cyclase activity. Infection of CHO cells with ExoY-producing strains of
P. aeruginosa resulted in the intracellular accumulation of
cAMP. cAMP accumulation within CHO cells depended on an
intact type III translocation apparatus, demonstrating that
ExoY is directly translocated into the eukaryotic cytosol.

MATERIALS AND METHODS
Bacterial Strains and Growth Conditions. P. aeruginosa
strains were maintained on Vogel–Bonner medium supplemented with antibiotics as required (8). For transformation of
P. aeruginosa, cells were made competent by using the MgCl2
method of Olsen et al. (9). As previously described, maximal
induction of the ExoS regulon required growth in a dialysate
of trypticase soy broth containing 10 mM nitrilotriacetic acid
(10). Plasmids were maintained in Escherichia coli DH5a, and
M13 bacteriophage clones were propagated in E. coli TG1 as
described (11). Antibiotics were used at the following concentrations: ampicillin, 100 mgyml; chloramphenicol, 30 mgyml;
tetracycline, 25 mgyml (E. coli) or 100 mgyml (P. aeruginosa);
and carbenicillin, 400 mgyml.
Cloning and Nucleotide Sequence Analysis. To clone exoY
from P. aeruginosa strain 388, an exoY-specific probe was
amplified with the primers 59-ACCATGCGTATCGACGGTCATC and 59-TTGCTGAGATGCTGGTCGACAC using
strain 388 chromosomal DNA as a template. A bank of strain
388 KpnI chromosomal restriction fragments was cloned in
pNOT19 and screened by hybridization with the exoY probe as
described (11). One positive clone was mapped to position
exoY by using restriction endonuclease digestion and Southern
blot analysis. Subclones were generated in M13 vectors by
using standard methods and subjected to nucleotide sequence
analysis with an ALF automated DNA sequencer and reagents
(Pharmacia). Analysis of nucleotide and protein sequences was
performed using the Genetics Computer Group (Madison,
WI) software.
Expression and Purification of recombinant ExoY (rExoY).
For expression and purification, exoY was cloned into the

Pseudomonas aeruginosa, an opportunistic pathogen of humans, most commonly infects individuals with cystic fibrosis,
impaired immune systems, or severe burns (1). Various virulence determinants have been shown to play a role in P.
aeruginosa pathogenesis, including proteases, alginate, phospholipases, and toxins. Our analysis of P. aeruginosa virulence
has focused on the exoenzyme S (ExoS) regulon, whose
expression is correlated with the spread of the bacterium from
epithelial colonization sites to the bloodstream (2). The members of the ExoS regulon are coordinately controlled at the
transcriptional level by ExsA, an Ara C-family regulatory
protein (3). ExsA regulates its own synthesis and a series of
operons encoding proteins involved in the intoxication of
eukaryotic cells by a process generally referred to as type III
secretion or polarized translocation. Type III secretion and
intoxication in P. aeruginosa are encoded by three classes of
gene products that include components of a secretory apparatus (ExsD, PscB-L, and PscN-U), proteins mediating the
translocation of effectors into the host cell cytoplasm (PopB
and PopD), and effector proteins (ExoS, ExoT, and ExoU)
that are postulated to disrupt normal cellular processes (2).
Type III-mediated effector translocation is postulated to in-
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pET16b (pETexoY) and pET23b (pET23exoY) vectors (Novagen). The pETexoY expression plasmid encodes a fusion
protein with 10 amino-terminal histidine residues, and
pET23exoY encodes a fusion protein with 6 carboxy-terminal
histidine residues. The purification of recombinant histidine
fusion proteins from E. coli lysates was performed by nickelaffinity chromatography. ExoY was amplified incorporating
XhoI restriction sites at both ends or with NheI and XhoI
restriction sites at the 59 and 39 ends, respectively. The
nucleotide sequence of amplified fragments was confirmed by
sequence analysis. Clones, confirmed by restriction endonuclease mapping, were transformed into BL21(DE3)pLysS (Novagen).
Ni21 affinity chromatography was performed as described
(11). After elution from the Ni21 resin, peak fractions were
immediately pooled and dialyzed against a buffer [20 mM
TriszHCl(pH 8.0)y250 mM NaCly6 mM MgCl2y0.2 mM CaCl2]
containing 2 mM DTT at 4°C. Glycerol was added to 10%, and
enzyme preparations were stored at 270°C. rExoY was quantitated by densitometry using BSA as a standard. Rabbit
antisera specific for ExoY was generated using standard
methodologies. Immunoblotting was performed as described
(12). Bound IgG was detected with 125I-protein A.
Site-Directed Mutagenesis. Site-directed mutations were
introduced into exoY by using a Sculptor mutagenesis kit
(Amersham). Primers K81M (59-CGAGAAGCCC[A]TGGTCGGGAAAC), K88I (59-GTTCGAGCTT[A]TCCCCTTCACC), D212N (59-AGGTCATAAT[T]GGCGGTCATCG), and
D214N (59-AGGAAGAGGT[T]ATAATCGGCG), were annealed to single-stranded M13 templates, and reactions were
performed according to the manufacturer’s instructions. Mutations were confirmed by nucleotide sequence analysis and
returned to the pETexoY expression plasmid as a SacII–RsrII
cassette.
Adenylate Cyclase Assays. Reactions (100 ml) contained 10
mM TriszHCl (pH 8.0), 6 mM MgCl2, 0.2 mM CaCl2, 2 mM
ATP, 2 mM DTT, and rExoY. Reactions were incubated at
30°C, stopped with the addition of 186 ml of ethanol (65% final
concentration), and incubated at room temperature for 5 min
to precipitate protein. Where indicated, reactions were treated
for 10 min with 5 mg of 39:59-cyclic nucleotide phosphodiesterase (Sigma) at 30°C before extraction with ethanol. Proteins
were precipitated by centrifugation (14,000 3 g) for 5 min, and
supernatants were collected, lyophilized, and suspended in 50
ml of distilled water. cAMP was resolved from ATP and AMP
and quantitated by using reverse-phase HPLC (13). Mobile
phases consisted of 0.1 M potassium phosphate, pH 6.0 (buffer
A) and 0.1 M potassium phosphate (pH 6.0) in 10% CH3OH
(buffer B). Samples were injected into a C-18 column (0.46
cm 3 15 cm) and resolved by washing for 5 min at 100% buffer
A, followed by an 8-min gradient to 100% buffer B, held for
5 min at 100% buffer B, and returned to 100% buffer A for 5
min. Absorbance was monitored at 259 nm. Retention times
were calculated using purified ATP, AMP, and cAMP as
standards. Stimulation of ExoY activity was measured in the
standard reaction containing bovine brain calmodulin (Sigma)
or a postnuclear extract (PNE) from Chinese hamster ovary
(CHO) cells (14).
Quantitation of cAMP in CHO cell lysates was performed
as follows. Twelve-well plates were seeded with 2 3 105 CHO
cells and cultured 18–24 hr in HAM’s F-12 nutrient mixture
(supplemented with 10% newborn calf serum, 50 unitsyml
penicillinystreptomycin, 2 mM L-glutamine, 0.12% sodium
bicarbonate, and 2.5 mM Hepes) at 37°C under 5% CO2.
Confluent monolayers (.95%) were washed with Dulbecco’s
phosphate-buffered saline, infected with 1 ml of medium
(lacking newborn calf serum and antibiotics) containing 1 3
107 bacteria (multiplicity of infection 5 25:1), and incubated at
37°C under 5% CO2. At the indicated times, cells were washed
twice with phosphate-buffered saline, harvested with 150 ml of
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4 mM EDTA, and heated to 100°C for 5 min. Lysates were
extracted with ethanol, lyophilized, suspended in 50 ml of 50
mM TriszHCl (pH 7.5)y4 mM EDTA, and assayed for cAMP
using a BioTrak [3H] cAMP kit (Amersham) according to the
manufacturer’s instructions. The protein content of the CHO
cell lysates was determined with a BCA protein assay kit
(Pierce). cAMP values were normalized to the protein content
of the cell lysate.

RESULTS
Identification, Cloning, and Nucleotide Sequence Analysis
of exoY. Previously, we generated and characterized transposon
mutants of P. aeruginosa that possess a defective type III
secretion apparatus (15). Comparison of the extracellular
protein profiles from wild-type and mutant strains demonstrated that in addition to ExoS, several other proteins were
absent in the secretion-deficient strains. By matching experimentally derived amino-terminal sequences of extracellular
proteins with sequences deduced from cloned genes that were
coordinately regulated with ExoS, we identified the major type
III-secreted products, with the exception of a 42-kDa protein
(16). To identify the 42-kDa protein, its amino-terminal sequence (MRIDGHRQVVSNATAQPGXLLR) was subjected
to a TFASTA search of sequences generated by the Pseudomonas Genome Project. This analysis revealed an ORF possessing
100% identity with the amino terminus of the 42-kDa protein.
Homology to the calmodulin-activated adenylate cyclases of
Bordetella pertussis and Bacillus anthracis was found immediately downstream of the amino-terminal sequence, in an
alternative reading frame. The proximity of the 42-kDa aminoterminal sequence to the region encoding adenylate cyclase
homology suggested that they were the same protein and that
an error in this early release of genomic sequence may account
for the difference in the reading frame. A chromosomal bank
from P. aeruginosa strain 388 was constructed and screened
with a specific probe amplified from genomic sequences.
Clones that hybridized with the probe were subjected to
nucleotide sequence analysis.
Nucleotide sequence analysis identified a 1,134-bp ORF
(378 residues) encoding a protein with a predicted molecular
mass of 41,673 Da, termed ExoY. The deduced aminoterminal sequence of ExoY and the amino-terminal sequence
of the secreted 42-kDa protein were identical (data not
shown). The lack of amino-terminal processing, the absence of
an amino-terminal signal sequence, and the presence of an
ExsA-binding site located immediately upstream of ExoY
support the notion that ExoY is a member of the ExoS regulon
and is coordinately regulated and secreted by a type III
mechanism (2, 16, 17).
Nucleotide sequence analysis confirmed that the amino
terminus of ExoY and the region of adenylate cyclase homology were in the same reading frame. BESTFIT and PILEUP
alignments of ExoY with the Bordetella pertussis (CyaA) and
Bacillus anthracis (EF) adenylate cyclases identified homologous regions (conserved regions I and II) extending from
residues 41–107 and 209–221 of ExoY (Fig. 1). Both of these
regions have previously been identified as areas of high
homology between CyaA and EF (18, 19). Conserved region
I contains an ATPyGTP-binding site A motif, which is thought
to play a role in contacting the a-phosphate of bound nucleotide (20). Conserved region II, common to ExoY, CyaA, and
EF, shares identity with a wide range of nucleotide-binding
proteins including phosphofructose kinase, pyruvate kinase,
and thymidylate kinase and is proposed to participate in
contacting the b- and g-phosphates of bound nucleotide (20).
A third short stretch of homology, conserved region III, which
has been described for CyaA and EF, is not present in ExoY
(Fig. 1 A). CyaA and EF each possess a binding site for
calmodulin, a eukaryotic protein that stimulates (CyaA) or is
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FIG. 1. (A) Schematic representation of the ExoY, CyaA, and EF adenylate cyclases. The positions of conserved regions I, II, and III are shown.
Solid boxes represent the calmodulin-binding domains of CyaA and EF. The glycine-rich repeats of CyaA (hatched), signal sequence (ss), and
protective antigen-binding site of EF are labeled. (B) PILEUP alignment of conserved regions I and II. Residues within CyaA and EF that are
homologous to ExoY are shaded. The position of ATP-binding site motif A and its consensus sequence are shown. Residues of ExoY altered by
site-directed mutagenesis are indicated by arrows.

required to activate (EF) adenylate cyclase activity. Significant
homology to the calmodulin-binding domains of CyaA and EF
was not detected in ExoY.
Expression and Purification of rExoY. rExoY was expressed
as a histidine-tagged fusion protein in E. coli pETexoY and
purified from bacterial lysates by using Ni21 affinity chromatography. Following elution from the Ni21 affinity column,
however, rExoY had a tendency to aggregate. In contrast to
other secreted effectors of the ExoS regulon (ExoS, ExoT, and
ExoU), which encode no cysteine residues, ExoY possesses five
cysteines. rExoY aggregated when dialyzed in the absence of
reducing agents, but remained soluble when dialysis was
performed in the presence of DTT or 2-mercaptoethanol (data
not shown). rExoY and all site-directed mutant proteins were
stored and assayed for adenylate cyclase activity in the presence of 2 mM DTT.
rExoY Possesses Adenylate Cyclase Activity. To determine
whether rExoY possessed adenylate cyclase activity, purified
rExoY (1 mM) was incubated in the presence of ATP and assay
buffer at 30°C for 4 hr. Formation of cAMP was monitored by
reverse-phase HPLC and calculated as a percentage of the
original ATP substrate (Fig. 2). Standard solutions containing
ATP, AMP, or cAMP were used to calculate retention times
of 3.6, 5.7, and 16.7 min., respectively (Fig. 2 A). Reaction
mixtures containing rExoY catalyzed the formation of a
product that eluted with authentic cAMP (Fig. 2D). This
product was not detected when rExoY was heated to 100°C for
5 min prior to the assay (data not shown) or when reactions
were treated with cAMP-59:39-phosphodiesterase (Fig. 2F).
Treatment of ATP and cAMP standards with phosphodiesterase resulted in the conversion of cAMP to AMP (Fig. 2E).
Formation of cAMP was not detected in control reactions
lacking enzyme (Fig. 2B) or containing a vector control extract
from BL21pLysS (Fig. 2C). When GTP was substituted for
ATP in the standard reaction, formation of cGMP was not
detected, suggesting that under the standard assay conditions,
ATP is the preferred substrate for ExoY (data not shown).

These data confirm that rExoY possesses adenylate cyclase
activity.
Several residues have been shown to be essential for the
adenylate cyclase activity of CyaA (21–24). Two residues
(Lys-81 and Lys-88) located within conserved region I are
predicted to be directly involved in ATP binding (Fig. 1B). Two
additional residues (Asp-212 and Asp-214), also thought to
play a role in contacting bound nucleotide, are located within
conserved region II (Fig. 1B) (20). All four residues are
conserved among EF, CyaA, and ExoY. To determine whether
these four residues were required for the adenylate cyclase
activity of ExoY, each was altered by site-directed mutagenesis. Lys-81 was changed to Met (K81M), Lys-88 to Ile (K88I),
and Asp-212 and -214 were changed to asparagines (D212N
and D214N). An additional clone was constructed to move the
histidine tag from the amino-terminal position (rExoY) to a
carboxyl-terminal position (r23ExoY). Of all of the recombinants tested, only rExoY and r23ExoY possessed detectable
adenylate cyclase activity (6.7 6 2.7 and 4.5 6 0.9 nmol of
cAMPyminzmg21 of ExoY, respectively). These data indicate
that each of the four conserved residues is essential for the
adenylate cyclase activity of ExoY.
rExoY Adenylate Cyclase Activity Is Stimulated by a Eukaryotic Factor. Calmodulin is absolutely required for EF
catalytic activity (25). Furthermore, the basal adenylate cyclase activity of CyaA is stimulated 500- to 1000-fold by
calmodulin (26). To determine whether calmodulin stimulated
the adenylate cyclase activity of ExoY, 1 mM rExoY or
r23ExoY was incubated in the absence or presence of 0.1 mM,
1 mM, or 10 mM calmodulin in a standard assay. Stimulation
of adenylate cyclase activity was undetectable (,2-fold) at all
three concentrations of calmodulin tested (data not shown).
These data suggest that calmodulin does not play a role in the
stimulation of ExoY adenylate cyclase activity.
To determine whether another eukaryotic protein stimulated the adenylate cyclase activity of ExoY, a crude extract of
cytosolic proteins (PNE) was prepared from CHO cells. In the
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3). Comparison of the stimulatory activity of three independently prepared extracts indicated that adenylate cyclase activity was increased at least 500-fold. The catalytic activity of
the site-specific mutants was not improved by the addition of
PNE, except for rExoYK88I, which now expressed 0.1% the
PNE-stimulated activity of rExoY.
In Vivo Effect of ExoY. Based on the model of type III
secretion, ExoY is predicted to be directly translocated by
adherent P. aeruginosa to the cytosol of target cells, resulting
in the elevation of intracellular cAMP levels. To address this
hypothesis, we took advantage of P. aeruginosa strain PA103,
which naturally lacks ExoS and ExoY expression (ref. 27; data
not shown). To eliminate effects from other known secreted
effector proteins, targeted mutations were introduced into the
exoU and exoT loci, resulting in expression strain
PA103DexoUexoT::Tc. An independent chromosomal mutation was also introduced into a gene encoding the putative
translocator protein PopD, PA103popD::V (16). Plasmids expressing native ExoY or a site-directed mutant of ExoYK81M,
which possessed no detectable adenylate cyclase activity, were
constructed and transformed into PA103DexoUexoT::Tc or
PA103popD::V. Transformants were cultured under inducing
conditions for ExoS production, and extracellular protein
profiles were examined by SDSyPAGE (Fig. 4A) and Western

FIG. 2. Reverse-phase HPLC analysis of cAMP production. The
elution profile of ATP, AMP, and cAMP (30 nmol) is shown in A,
standard reactions lacking enzyme in B, reactions containing a control
extract from BL21pLysS in C, and 1.0 mM rExoY in D. ATP and cAMP
(30 nmol) treated with 39:59-cyclic nucleotide phosphodiesterase is
shown in E. A reaction identical to that seen in D treated with 5 mg
of 39:59-cyclic nucleotide phosphodiesterase for 10 min at 30°C is
shown in F.

absence of rExoY, PNE possessed no detectable adenylate
cyclase activity (data not shown). In contrast, the addition of
PNE (1–30 mg) to rExoY (1 mM) stimulated adenylate cyclase
activity in a dose-dependent manner (Fig. 3). PNE heated to
100°C for 5 min possessed no stimulatory activity, suggesting
that the factor is proteinaceous in nature. An irrelevant
protein, BSA, did not stimulate adenylate cyclase activity (Fig.

FIG. 3. A eukaryotic factor stimulates rExoY adenylate cyclase
activity. rExoY (1.0 mM) was assayed for adenylate cyclase activity in
the presence or absence of PNE from CHO cells for 30 min under
standard conditions. p indicates that PNE was heated to 100°C for 5
min prior to addition to the assay mixture. Calmodulin (CaM, 10 mM)
or 50 mgyml BSA did not stimulate rExoY adenylate cyclase activity.

FIG. 4. Extracellular protein profiles of ExoY-expressing strains. P.
aeruginosa strains (as in Table 1; wt, PA103; exsA, PA103exsA::V;
exoUyT, PA103DexoUexoT::Tc; popD, PA103popD::V) were grown to
an OD540 between 4.0 and 5.0, and extracellular fractions were
prepared. A is a Coomassie-stained gel of concentrated supernatants.
Molecular-mass markers (in kDa) are labeled on the left of A. B–E are
immunoblots of gels identical to A probed with antisera against ExoU,
ExoSyT, ExoY, and PopD, respectively. For ExoY expression in strain
PA103, ExoY was amplified with its native promoter and cloned into
pUCP18. p denotes the expression of a catalytically (K81M) inactive
form of ExoY.

Microbiology: Yahr et al.

Proc. Natl. Acad. Sci. USA 95 (1998)

blot analysis (Fig. 4 B–E). Wild-type PA103 produces and
secretes ExoU, ExoT, and PopD, but not ExoY. Insertional
inactivation of the transcriptional activator exsA results in a
generalized repression of the entire type III system (absence of
ExoU, ExoT, and PopD). The specific mutations in the effector proteins ExoU and ExoT eliminate their expression but
have no effect on the translocation protein PopD. ExoY and
the catalytically inactive mutant K81M (p) are synthesized and
secreted from PA103DexoUexoT::Tc. The translocation mutant PA103popD::V makes no PopD but is competent for
synthesis and secretion of ExoU, ExoT, and ExoY (in trans).
To determine the in vivo effect of ExoY expression, CHO
cells were infected with P. aeruginosa strains for 225 min. CHO
cells were lysed and assayed for cAMP. Comparison of uninfected CHO cells to those infected with the vector control
strain (PA103DexoUexoT::Tc, pUCP18) demonstrated that the
parental strain has no significant effect on the morphology of
CHO cells or levels of cAMP (Table 1). In contrast, following
infection with an ExoY-expressing strain, CHO cells showed a
rounded morphology that correlated to increased cAMP levels. The changes in morphology and cAMP levels were not
detected following infection with the catalytically inactive
K81M mutant of ExoY (Fig. 5). As a positive control, the
morphological responses of the CHO cells to heat-labile
enterotoxin (LT) and pertussis toxin (PT) were determined
(28). Intoxication with LT or PT elicited an elongation response or a clustering response, respectively (data not shown).
The differential morphological response of CHO cells to ExoY
relative to LT or PT is unclear, but may involve the magnitude
of the change in intracellular cAMP levels or may be related
to differences in the subcellular distribution of each toxin.
After infection with the popD::V-expressing ExoY, no
changes in CHO cell morphology or cAMP levels were detected, indicating that delivery of ExoY depended on type
III-mediated translocation. Pretreatment of CHO cells with
cytochalasin D, which prevents bacterial invasion, followed by
infection with an ExoY-expressing strain resulted in elevated
cAMP levels, suggesting that extracellular bacteria are able to
mediate ExoY intoxication. Treatment of the CHO cell lysate
with phosphodiesterase prevented detection of cAMP, which
confirmed the product specificity of ExoY. A kinetic analysis
of cAMP accumulation in CHO cells demonstrated a rapid
increase in cAMP after 100 min of infection with P. aeruginosa
expressing ExoY (Fig. 5). These data suggest that ExoY is
directly translocated from the bacterial cell to the eukaryotic
cytosol and that elevated cAMP levels are associated with the
rounded morphology of the CHO cells. Furthermore, these
data demonstrate that the elevation of cAMP is directly
attributable to the adenylate cyclase activity of ExoY.
Table 1.
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FIG. 5. Kinetics of cAMP accumulation in infected CHO cells.
CHO cells were infected with PA103DexoUexoT::Tc expressing either
native ExoY or catalytically inactive ExoYK81M. At the indicated
times, lysate fractions were prepared and assayed for cAMP. Values
are the average of three wells and reported as pmols of cAMP per 144
mg of cellular protein per well.

DISCUSSION
The identification of ExoY represents the discovery of a
unique bacterial protein possessing adenylate cyclase activity.
Two properties distinguish ExoY from the adenylate cyclases
of Bordetella pertussis and Bacillus anthracis. In this article, we
demonstrate that ExoY is an adenylate cyclase delivered into
eukaryotic cells via a type III translocation mechanism. Evidence to support this conclusion includes the coordinate
regulation and secretion of ExoY by the ExoS regulon of P.
aeruginosa. In previous studies, this regulon has been shown to
encode type III secretion, translocation, and effector proteins
(2, 15, 16). The amino-terminal region in ExoY is not processed during secretion, and the carboxyl-terminal region does
not contain a glycine-rich repeat region; these data eliminate
type II and type I mechanisms of secretion. Infection of
eukaryotic cells with P. aeruginosa strains, producing catalytically active ExoY, results in an elevation of intracellular
cAMP and cell-morphology changes. Cell-morphology
changes or cAMP accumulation were not observed when the
type III translocation apparatus was compromised by mutation
(popD::V), when a catalytically inactive form of ExoY was
provided in trans, or when rExoY was added directly to cells
(data not shown). These data are consistent with a type III
translocation mechanism mediating the intoxication of cells by
ExoY.
Each of the known adenylate cyclase toxins is secreted from
the bacterium and enters host cells by a distinct mechanism.
ExoY enters cells by a translocation mechanism that is coupled

Elevation of cAMP levels in P. aeruginosa-infected CHO cells

P. aeruginosa strain

Plasmid

cAMP, pmol*

Morphology
change†

Uninfected
PA103DexoUexoT::Tc
PA103DexoUexoT::Tc
PA103DexoUexoT::Tc
PA103popD::V
PA103DexoUexoT::Tc
PA103DexoUexoT::Tc

NA
pUCP
pUCPexoY
pUCPexoY K81M‡
pUCPexoY
pUCPexoY
pUCPexoY

,0.5
,0.5
136.9 6 4.5
,0.5
,0.5
95.8 6 16.8§
,0.5¶

2
2
1
2
2
NA
1

NA, not applicable.
*Data are reported as pmol of cAMP normalized to 417 mg of cellular protein per well.
†CHO cell morphology change is defined as the change from an elongated triangular shape to a rounded
morphology.
‡K81M is a catalytically inactive mutant of ExoY.
§Cells were pretreated with cytochalasin D for 30 min prior to infection.
¶CHO cell lysate was treated with 59:39-cAMP phosphodiesterase prior to assaying for cAMP.
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to type III secretion from P. aeruginosa. CyaA of Bordetella
pertussis is secreted by a type I mechanism for which a-hemolysin of E. coli serves as the prototypical protein. Like a-hemolysin, CyaA possesses glycine-rich carboxy-terminal repeat
sequences that are required for binding to host cells, hemolytic
activity, and subsequent translocation of the catalytic domain
to the eukaryotic cytosol (29). Bacillus anthracis-encoded EF
is secreted by the general secretory pathway (type II) and
enters cells by receptor-mediated endocytosis (30). The entry
of EF depends on the expression and secretion of protective
antigen, which serves as the binding subunit of this toxin.
Unlike CyaA and EF, which are secreted and may exert their
effects at sites distal from the site of infection, the mechanism
of delivery to host cells limits ExoY intoxication to sites of
colonization. The production of ExoY may play a role in the
protection of the bacterium from local phagocytic cells. Both
CyaA and EF have been shown to suppress immune function
(31–34).
A second property of ExoY is the stimulation of adenylate
cyclase activity by a eukaryotic factor that is distinct from
calmodulin. Calmodulin is absolutely required for the detection of adenylate cyclase activity from EF and stimulates the
basal activity of CyaA 500- to 1000-fold (25, 26). Both CyaA
and EF possess domains that are required for calmodulin
binding, and peptides derived from these regions have been
shown to directly bind calmodulin (35, 36). In contrast, ExoY
lacks homology with the CyaAyEF calmodulin-binding domains, and the addition of calmodulin to enzyme assays has
only a marginal effect on activity. We found that the basal
activity of ExoY was stimulated at least 500-fold by the
addition of PNE from CHO cells and when heated, this extract
failed to activate ExoY. In addition, high levels of cAMP were
detected when CHO cells were infected with P. aeruginosa
strains expressing ExoY. Taken together, these observations
indicate that a eukaryotic protein distinct from calmodulin
stimulates the adenylate cyclase activity of ExoY. The stimulation of ExoY adenylate cyclase activity by a eukaryotic
cofactor may represent a regulatory strategy to prevent the
generation of cAMP within the bacterium before intoxication
of host cells. This regulatory strategy can also be applied to
ExoS and ExoT, which demonstrate an absolute requirement
for FAS to express ADP ribosyltransferase activity under
physiological conditions. The discovery of ExoY and the
eventual identification of the eukaryotic activator will aid in
the understanding of the relationship between type III secretion, epithelial damage, and bacterial dissemination.
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